Mumbai-based BDR Pharmaceutical has announced the launch of the first-of-its kind generic drug, Zisavel Capsules, for the treatment of invasive aspergillosis and mucormycosis. Zisavel belongs to the family of isavuconazole, a class of medications called azole antifungals. Isavuconazole plays an important role in the treatment of invasive aspergillosis.

The product will be available as 100 mg capsules and is the first line of treatment for the aforementioned fungal infections. The price of the generic drug will be Rs 7992, for 7 capsules which is one-third the cost of present therapy available by Innovators.

BDR Pharmaceutical aims to reduce the cost of therapy for invasive fungal diseases with isavuconazole to be on par with voriconazole and posaconazole (new-generation anti-fungal agents), making it more accessible to patients who are unable to afford it currently.

The global antifungal drugs market size was valued at $15.80 billion in 2022 and is projected to witness at a compound annual growth rate (CAGR) of 3.74% from 2023 to 2030. The growing prevalence of fungal infections such as aspergillosis and candidiasis is one of the key factors propelling the market. The India anti-fungal drugs market is estimated to be valued at $1.56273 Bn in 2021 and is expected to exhibit a CAGR of 10.49% over the forecast period (2021-2030).